Retinal Vein Occlusion (RVO) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Retinal Vein Occlusion (RVO) Market Outlook

Thelansis’s “Retinal Vein Occlusion (RVO) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Retinal Vein Occlusion treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Retinal Vein Occlusion (RVO) Overview

Retinal vein occlusions (RVO) constitute a heterogeneous group of disorders characterized by impaired venous return from the retinal circulation. Classification of RVO can be subdivided into branch retinal vein occlusion (BRVO), hemiretinal vein occlusion (HRVO), and central retinal vein occlusion (CRVO), depending on the obstruction site. An occlusion within or posterior to the optic nerve head is termed CRVO, an occlusion at the major bifurcation is classified as HRVO, and any obstruction within a tributary is identified as BRVO. HRVO is often considered a distinct condition, exhibiting characteristics intermediate between BRVO and CRVO. Typical atherosclerosis risk factors are commonly associated with all types of RVO, though vein occlusions can also arise secondary to other processes such as inflammation, vasospasm, or compression. Major risk factors for BRVO include systemic arterial hypertension, arteriosclerosis, and diabetes, with additional associations reported, including thrombophilia. Patients with RVO are at risk of vision loss due to several complications from interrupted blood flow, including macular edema, macular ischemia, optic neuropathy, vitreous hemorrhage, and tractional retinal detachment. However, symptoms of RVO can be subtle or absent, particularly in cases of mild severity or when the affected area does not involve the macula. Visual field abnormalities are variably present but are uncommonly symptomatic. Diagnosing retinal vein occlusions is clinical, necessitating thorough examinations to evaluate indications for potential treatment. Routine examination includes assessment of intraocular pressure, slit-lamp examination with undilated gonioscopy, and dilated funduscopy to detect glaucoma, ocular neovascularization, and macular edema. Central venous pressure can be predictive of disease severity. Management of retinal vein occlusion primarily focuses on addressing the disorder's consequences rather than re-establishing normal venous circulation. Faricimab is the first and only bispecific antibody approved by the FDA for the treatment of the eye. The FDA has also approved farcical (Vabysmo; Genentech) for the treatment of macular edema following retinal vein occlusion (RVO).

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2023-2033

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: